The revised text sets the regulated monetary adjustment at a 7.4% reduction. This smartly corrects calculations by expanding the review to 24 months, up to December 2025.
Additionally, it defines two distinct rates: for international comparisons and for current price updates. The update broadens adjustments to 40 entries, a 74 percent increase impacting specialized therapies. The text integrates 34 new markets and 5 subcategories into the direct control regime. Crucially, it introduces practical units like kits for cystic fibrosis and separates formulas, such as tenofovir variations.
Furthermore, it explicitly names the 8 markets reviewed by request, including ibuprofen and also thalidomide. This update establishes pricing architecture designed to foster the sustainability of the health system.
